Missri J C, Ide P A, Williams C B
Heart Lung. 1984 Mar;13(2):177-82.
Although it is certain that thrombolytic therapy is effective in achieving reperfusion in an acutely thrombosed coronary artery, the ability of such restoration of flow to preserve myocardial function must be demonstrated. It must also be determined if the gains in contractile function are of sufficient magnitude to reduce morbidity and deaths after infarction. The patient population that can potentially benefit from this procedure is largely unknown. However, it is certain that the institution of thrombolytic therapy must begin in the early hours of acute infarction. The vast majority of patients with MI are cared for in hospitals that do not perform cardiac catheterizations. Thus the question of efficacy of intravenous fibrinolytic therapy is very important. Randomized clinical trials are already in progress and answers to important questions are forthcoming.
虽然可以肯定溶栓疗法在使急性血栓形成的冠状动脉再灌注方面是有效的，但必须证明这种血流恢复保留心肌功能的能力。还必须确定收缩功能的改善幅度是否足以降低梗死后的发病率和死亡率。可能从该手术中获益的患者群体很大程度上尚不清楚。然而，可以肯定的是，溶栓治疗必须在急性梗死的早期开始。绝大多数心肌梗死患者在不进行心导管插入术的医院接受治疗。因此，静脉内纤维蛋白溶解疗法的疗效问题非常重要。随机临床试验已经在进行中，重要问题的答案即将揭晓。
